Tandem Selling General Administrative vs Total Revenue Analysis

TNDM Stock

USD 51.03 0.36 0.70%

Tandem Diabetes financial indicator trend analysis is much more than just breaking down Tandem Diabetes Care prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tandem Diabetes Care is a good investment. Please check the relationship between Tandem Diabetes Selling General Administrative and its Total Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

Selling General Administrative vs Total Revenue

Selling General Administrative vs Total Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tandem Diabetes Care Selling General Administrative account and Total Revenue. At this time, the significance of the direction appears to have totally related.

The correlation between Tandem Diabetes' Selling General Administrative and Total Revenue is 0.99. Overlapping area represents the amount of variation of Selling General Administrative that can explain the historical movement of Total Revenue in the same time period over historical financial statements of Tandem Diabetes Care, assuming nothing else is changed. The correlation between historical values of Tandem Diabetes' Selling General Administrative and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling General Administrative of Tandem Diabetes Care are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Selling General Administrative i.e., Tandem Diabetes' Selling General Administrative and Total Revenue go up and down completely randomly.

Correlation Coefficient

0.99

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Selling General Administrative

Total Revenue

Total revenue comprises all receipts Tandem Diabetes Care generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most indicators from Tandem Diabetes' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tandem Diabetes Care current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

At this time, Tandem Diabetes' Selling General Administrative is very stable compared to the past year. As of the 23rd of May 2024, Tax Provision is likely to grow to about 2.5 M, while Enterprise Value Over EBITDA is likely to drop (20.24).

	2021	2023	2024 (projected)
Interest Expense	4.3M	7.6M	5.8M
Depreciation And Amortization	13.8M	15.7M	9.4M

Interest Expense Depreciation And Amortization

Tandem Diabetes fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.97	0.94	0.96	0.88	0.98	0.94	0.9	-0.86	0.82	0.65	0.94	0.77	0.69	0.91	0.99	0.23	0.89	0.97	0.94	0.92	0.86	0.86	0.96	0.89	1.0
Short Long Term Debt Total	0.97		0.85	0.93	0.76	0.96	0.96	0.97	-0.82	0.84	0.57	0.97	0.86	0.67	0.83	0.94	0.15	0.78	0.92	0.98	0.94	0.89	0.77	0.99	0.94	0.95
Other Current Liab	0.94	0.85		0.95	0.85	0.95	0.87	0.81	-0.89	0.75	0.51	0.85	0.68	0.66	0.85	0.96	0.26	0.97	0.93	0.82	0.87	0.82	0.88	0.88	0.82	0.94
Total Current Liabilities	0.96	0.93	0.95		0.77	0.98	0.96	0.91	-0.93	0.88	0.5	0.96	0.86	0.61	0.79	0.96	0.12	0.92	0.9	0.9	0.97	0.93	0.84	0.95	0.95	0.94
Total Stockholder Equity	0.88	0.76	0.85	0.77		0.81	0.72	0.63	-0.76	0.65	0.76	0.7	0.42	0.64	0.97	0.88	0.36	0.86	0.9	0.68	0.67	0.58	0.93	0.72	0.62	0.9
Other Liab	0.98	0.96	0.95	0.98	0.81		0.94	0.94	-0.92	0.85	0.52	0.95	0.83	0.7	0.84	0.98	0.2	0.9	0.95	0.93	0.96	0.91	0.86	0.97	0.92	0.97
Property Plant And Equipment Net	0.94	0.96	0.87	0.96	0.72	0.94		0.92	-0.84	0.89	0.59	1.0	0.88	0.59	0.76	0.92	0.07	0.81	0.86	0.94	0.97	0.89	0.77	0.97	0.98	0.91
Net Debt	0.9	0.97	0.81	0.91	0.63	0.94	0.92		-0.79	0.81	0.35	0.93	0.9	0.65	0.72	0.89	0.1	0.73	0.87	0.97	0.93	0.92	0.68	0.97	0.92	0.88
Retained Earnings	-0.86	-0.82	-0.89	-0.93	-0.76	-0.92	-0.84	-0.79		-0.9	-0.44	-0.85	-0.75	-0.64	-0.71	-0.89	-0.19	-0.9	-0.81	-0.74	-0.89	-0.86	-0.91	-0.81	-0.83	-0.85
Accounts Payable	0.82	0.84	0.75	0.88	0.65	0.85	0.89	0.81	-0.9		0.48	0.89	0.81	0.45	0.65	0.84	-0.07	0.77	0.73	0.79	0.87	0.81	0.79	0.83	0.88	0.8
Cash	0.65	0.57	0.51	0.5	0.76	0.52	0.59	0.35	-0.44	0.48		0.56	0.27	0.41	0.72	0.59	0.24	0.51	0.57	0.51	0.46	0.32	0.61	0.52	0.48	0.66
Non Current Assets Total	0.94	0.97	0.85	0.96	0.7	0.95	1.0	0.93	-0.85	0.89	0.56		0.91	0.59	0.74	0.91	0.05	0.79	0.85	0.95	0.98	0.91	0.75	0.97	0.99	0.91
Non Currrent Assets Other	0.77	0.86	0.68	0.86	0.42	0.83	0.88	0.9	-0.75	0.81	0.27	0.91		0.44	0.48	0.74	-0.15	0.6	0.66	0.86	0.94	0.93	0.54	0.87	0.95	0.72
Other Assets	0.69	0.67	0.66	0.61	0.64	0.7	0.59	0.65	-0.64	0.45	0.41	0.59	0.44		0.67	0.7	0.78	0.63	0.72	0.65	0.6	0.55	0.65	0.65	0.51	0.71
Cash And Short Term Investments	0.91	0.83	0.85	0.79	0.97	0.84	0.76	0.72	-0.71	0.65	0.72	0.74	0.48	0.67		0.91	0.35	0.83	0.94	0.79	0.69	0.62	0.89	0.81	0.66	0.93
Net Receivables	0.99	0.94	0.96	0.96	0.88	0.98	0.92	0.89	-0.89	0.84	0.59	0.91	0.74	0.7	0.91		0.23	0.93	0.98	0.91	0.9	0.85	0.89	0.94	0.87	0.99
Common Stock Total Equity	0.23	0.15	0.26	0.12	0.36	0.2	0.07	0.1	-0.19	-0.07	0.24	0.05	-0.15	0.78	0.35	0.23		0.29	0.3	0.13	0.08	0.06	0.3	0.13	-0.03	0.27
Common Stock Shares Outstanding	0.89	0.78	0.97	0.92	0.86	0.9	0.81	0.73	-0.9	0.77	0.51	0.79	0.6	0.63	0.83	0.93	0.29		0.89	0.74	0.81	0.77	0.9	0.81	0.76	0.9
Short Term Investments	0.97	0.92	0.93	0.9	0.9	0.95	0.86	0.87	-0.81	0.73	0.57	0.85	0.66	0.72	0.94	0.98	0.3	0.89		0.9	0.83	0.8	0.85	0.92	0.8	0.99
Non Current Liabilities Total	0.94	0.98	0.82	0.9	0.68	0.93	0.94	0.97	-0.74	0.79	0.51	0.95	0.86	0.65	0.79	0.91	0.13	0.74	0.9		0.92	0.87	0.69	0.99	0.92	0.92
Inventory	0.92	0.94	0.87	0.97	0.67	0.96	0.97	0.93	-0.89	0.87	0.46	0.98	0.94	0.6	0.69	0.9	0.08	0.81	0.83	0.92		0.97	0.75	0.95	0.98	0.89
Other Current Assets	0.86	0.89	0.82	0.93	0.58	0.91	0.89	0.92	-0.86	0.81	0.32	0.91	0.93	0.55	0.62	0.85	0.06	0.77	0.8	0.87	0.97		0.68	0.91	0.94	0.83
Other Stockholder Equity	0.86	0.77	0.88	0.84	0.93	0.86	0.77	0.68	-0.91	0.79	0.61	0.75	0.54	0.65	0.89	0.89	0.3	0.9	0.85	0.69	0.75	0.68		0.74	0.69	0.87
Total Liab	0.96	0.99	0.88	0.95	0.72	0.97	0.97	0.97	-0.81	0.83	0.52	0.97	0.87	0.65	0.81	0.94	0.13	0.81	0.92	0.99	0.95	0.91	0.74		0.95	0.94
Property Plant And Equipment Gross	0.89	0.94	0.82	0.95	0.62	0.92	0.98	0.92	-0.83	0.88	0.48	0.99	0.95	0.51	0.66	0.87	-0.03	0.76	0.8	0.92	0.98	0.94	0.69	0.95		0.86
Total Current Assets	1.0	0.95	0.94	0.94	0.9	0.97	0.91	0.88	-0.85	0.8	0.66	0.91	0.72	0.71	0.93	0.99	0.27	0.9	0.99	0.92	0.89	0.83	0.87	0.94	0.86

Click cells to compare fundamentals

Tandem Diabetes Account Relationship Matchups

Tandem Diabetes fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	326.1M	716.4M	905.1M	1.1B	952.7M	1.0B
Other Current Liab	71.5M	70.5M	84.4M	77.6M	84.6M	88.8M
Total Current Liabilities	99.4M	103.9M	131.9M	165.3M	195.3M	205.0M
Total Stockholder Equity	195.0M	366.3M	433.1M	439.9M	313.6M	160.8M
Other Liab	17.7M	27.4M	34.8M	36.1M	41.5M	43.6M
Property Plant And Equipment Net	48.5M	69.8M	77.9M	179.2M	164.3M	172.5M
Net Debt	(30.8M)	133.7M	243.5M	247.4M	356.8M	374.6M
Retained Earnings	(624.8M)	(659.2M)	(634.6M)	(729.2M)	(951.8M)	(904.2M)
Accounts Payable	17.7M	17.8M	28.0M	55.7M	49.6M	52.1M
Cash	51.2M	94.6M	71.2M	172.5M	58.9M	65.4M
Non Current Assets Total	50.0M	79.2M	93.6M	202.8M	204.7M	214.9M
Non Currrent Assets Other	708K	580K	9.1M	19.0M	37.6M	39.4M
Other Assets	708K	29.2M	9.1M	10.7M	12.3M	12.9M
Cash And Short Term Investments	176.5M	484.9M	623.8M	616.9M	467.9M	242.0M
Net Receivables	46.6M	82.2M	110.7M	114.7M	105.6M	110.8M
Common Stock Total Equity	59K	14.3M	64K	65K	74.8K	71.0K
Common Stock Shares Outstanding	58.5M	61.0M	64.3M	64.1M	65.0M	68.2M
Short Term Investments	125.3M	390.3M	552.6M	444.4M	409.0M	429.5M
Liabilities And Stockholders Equity	326.1M	716.4M	905.1M	1.1B	952.7M	1.0B
Non Current Liabilities Total	31.7M	246.3M	340.2M	447.5M	443.8M	466.0M
Inventory	49.1M	63.7M	68.6M	111.1M	157.9M	165.8M
Other Current Assets	4.0M	6.4M	8.4M	7.2M	16.6M	17.4M
Other Stockholder Equity	819.6M	1.0B	1.1B	1.2B	1.3B	669.8M
Total Liab	131.1M	350.1M	472.0M	612.8M	639.0M	671.0M
Property Plant And Equipment Gross	48.5M	50.0M	77.9M	179.2M	217.1M	228.0M
Total Current Assets	276.1M	637.2M	811.5M	850.0M	748.0M	785.4M
Accumulated Other Comprehensive Income	122K	220K	(616K)	(1.8M)	1.4M	1.4M
Common Stock	59K	62K	64K	65K	66K	41.6K
Property Plant Equipment	32.9M	50.0M	50.4M	68.6M	78.8M	82.8M
Current Deferred Revenue	3.9M	6.1M	10.2M	18.8M	44.0M	46.2M
Intangible Assets	777K	8.8M	6.6M	4.6M	2.8M	3.5M
Net Tangible Assets	195.0M	366.3M	433.1M	439.9M	505.9M	531.2M
Retained Earnings Total Equity	(624.8M)	(659.2M)	(634.6M)	(729.2M)	(656.3M)	(689.1M)
Capital Surpluse	819.6M	1.0B	1.1B	1.2B	1.3B	776.1M

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Tandem Diabetes Care using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Fix portfolios for free

When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:

How To Invest In Tandem

Details

Is Tandem Stock a good investment?

Details

What is Tandem Diabetes' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

Note that the Tandem Diabetes Care information on this page should be used as a complementary analysis to other Tandem Diabetes' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Tandem Stock analysis

When running Tandem Diabetes' price analysis, check to measure Tandem Diabetes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tandem Diabetes is operating at the current time. Most of Tandem Diabetes' value examination focuses on studying past and present price action to predict the probability of Tandem Diabetes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tandem Diabetes' price. Additionally, you may evaluate how the addition of Tandem Diabetes to your portfolios can decrease your overall portfolio volatility.

	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Commodity Directory Find actively traded commodities issued by global exchanges
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Transaction History View history of all your transactions and understand their impact on performance
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	CEOs Directory Screen CEOs from public companies around the world
	FinTech Suite Use AI to screen and filter profitable investment opportunities

Is Tandem Diabetes' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.37)

Earnings Share

(2.16)

Revenue Per Share

11.817

Quarterly Revenue Growth

0.132

Return On Assets

(0.1)

The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tandem Selling General Administrative vs Total Revenue Analysis

Selling General Administrative vs Total Revenue

Selling General Administrative vs Total Revenue Correlation Analysis

Correlation Coefficient

Selling General Administrative

Total Revenue

Tandem Diabetes fundamental ratios Correlations

Tandem Diabetes Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Tandem Diabetes fundamental ratios Accounts

Becoming a Better Investor with Macroaxis

Build Optimal Portfolios

Align your risk with return expectations

Complementary Tools for Tandem Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Net Receivables	+ 0.99	Total Assets
Total Liab	+ 0.99	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 0.99	Non Current Assets Total
Total Current Assets	+ 0.99	Net Receivables

Retained Earnings	- 0.93	Total Current Liabilities
Retained Earnings	- 0.92	Other Liab
Other Stockholder Equity	- 0.91	Retained Earnings
Common Stock Shares Outstanding	- 0.9	Retained Earnings
Accounts Payable	- 0.9	Retained Earnings
Inventory	- 0.89	Retained Earnings